Association of SARS-CoV-2 nucleocapsid viral antigen and the receptor for advanced glycation end products with development of severe disease in patients presenting to the emergency department with COVID-19.
Association of SARS-CoV-2 nucleocapsid viral antigen and the receptor for advanced glycation end products with development of severe disease in patients presenting to the emergency department with COVID-19.
复制标题
DOI:
10.3389/fimmu.2023.1130821
复制
发表时间:
2023
影响因子:
7.3
通讯作者:
中科院分区:
文献类型:
--
作者:
There remains a need to better identify patients at highest risk for developing severe Coronavirus Disease 2019 (COVID-19) as additional waves of the pandemic continue to impact hospital systems. We sought to characterize the association of receptor for advanced glycation end products (RAGE), SARS-CoV-2 nucleocapsid viral antigen, and a panel of thromboinflammatory biomarkers with development of severe disease in patients presenting to the emergency department with symptomatic COVID-19. Blood samples were collected on arrival from 77 patients with symptomatic COVID-19, and plasma levels of thromboinflammatory biomarkers were measured. Differences in biomarkers between those who did and did not develop severe disease or death 7 days after presentation were analyzed. After adjustment for multiple comparisons, RAGE, SARS-CoV-2 nucleocapsid viral antigen, interleukin (IL)-6, IL-10 and tumor necrosis factor receptor (TNFR)-1 were significantly elevated in the group who developed severe disease (all p<0.05). In a multivariable regression model, RAGE and SARS-CoV-2 nucleocapsid viral antigen remained significant risk factors for development of severe disease (both p<0.05), and each had sensitivity and specificity >80% on cut-point analysis. Elevated RAGE and SARS-CoV-2 nucleocapsid viral antigen on emergency department presentation are strongly associated with development of severe disease at 7 days. These findings are of clinical relevance for patient prognostication and triage as hospital systems continue to be overwhelmed. Further studies are warranted to determine the feasibility and utility of point-of care measurements of these biomarkers in the emergency department setting to improve patient prognostication and triage.
登录
查看更多内容
影响因子:
6.1
作者:
Chiappalupi S;Salvadori L;Vukasinovic A;Donato R;Sorci G;Riuzzi F
通讯作者:
Riuzzi F
DOI:
10.3390/diagnostics12010176
发表时间:
2022-01-12
期刊:
Diagnostics (Basel, Switzerland)
影响因子:
--
作者:
Ceci FM;Fiore M;Gavaruzzi F;Angeloni A;Lucarelli M;Scagnolari C;Bonci E;Gabanella F;Di Certo MG;Barbato C;Petrella C;Greco A;Vincentiis M;Ralli M;Passananti C;Poscia R;Minni A;Ceccanti M;Tarani L;Ferraguti G
通讯作者:
Ferraguti G
影响因子:
38.9
作者:
Jabaudon M;Blondonnet R;Pereira B;Cartin-Ceba R;Lichtenstern C;Mauri T;Determann RM;Drabek T;Hubmayr RD;Gajic O;Uhle F;Coppadoro A;Pesenti A;Schultz MJ;Ranieri MV;Brodska H;Mrozek S;Sapin V;Matthay MA;Constantin JM;Calfee CS
通讯作者:
Calfee CS
影响因子:
8.1
作者:
Lim A;Radujkovic A;Weigand MA;Merle U
通讯作者:
Merle U
DOI:
10.1016/j.ajem.2020.12.076
发表时间:
2021-03
期刊:
The American journal of emergency medicine
影响因子:
--
作者:
Hariyanto TI;Japar KV;Kwenandar F;Damay V;Siregar JI;Lugito NPH;Tjiang MM;Kurniawan A
通讯作者:
Kurniawan A